Search Result

Results for "

hepatocellular carcinoma (HCC)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Anaplastic lymphoma kinase (ALK) (2) Antibiotic (1) Apoptosis (12) Autophagy (2) Bacterial (2) Bcl-2 Family (1) CaMK (1) DNA/RNA Synthesis (1) Endogenous Metabolite (3) Epigenetic Reader Domain (1) Estrogen Receptor/ERR (1) FGFR (3) Fungal (1) HBV (1) HCV (1) HDAC (2) Histone Acetyltransferase (1) MicroRNA (1) mTOR (1) Na+/K+ ATPase (1) p38 MAPK (1) PKA (1) PROTACs (2) RAR/RXR (1) Reactive Oxygen Species (2) SARS-CoV (1) SphK (2) STAT (2) Survivin (1) TGF-β Receptor (2) ULK (1) VEGFR (1) Wnt (2) β-catenin (1)
By Research Areas:	Cancer (39) Cardiovascular Disease (1) Infection (5) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (1)

By Targets:

Akt (2)

Anaplastic lymphoma kinase (ALK) (2)

Antibiotic (1)

Apoptosis (12)

Autophagy (2)

Bacterial (2)

Bcl-2 Family (1)

CaMK (1)

DNA/RNA Synthesis (1)

Endogenous Metabolite (3)

Epigenetic Reader Domain (1)

Estrogen Receptor/ERR (1)

FGFR (3)

Fungal (1)

HBV (1)

HCV (1)

HDAC (2)

Histone Acetyltransferase (1)

MicroRNA (1)

mTOR (1)

Na+/K+ ATPase (1)

p38 MAPK (1)

PKA (1)

PROTACs (2)

RAR/RXR (1)

Reactive Oxygen Species (2)

SARS-CoV (1)

SphK (2)

STAT (2)

Survivin (1)

TGF-β Receptor (2)

ULK (1)

VEGFR (1)

Wnt (2)

β-catenin (1)

By Research Areas:

Cancer (39)

Cardiovascular Disease (1)

Infection (5)

Inflammation/Immunology (1)

Metabolic Disease (1)

Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13267

Droxinostat 2 Publications Verification NS 41080	HDAC Apoptosis	Cancer
Droxinostat (NS 41080) is a histone deacetylase (HDAC) inhibitor. Droxinostat selectively inhibits HDAC3, HDAC6, and HDAC8 with IC₅₀ values of 16.9 μM, 2.47 μM, and 1.46 μM, respectively. Droxinostat can be used for the research of hepatocellular carcinoma (HCC) .

HY-N11429

Glycochenodeoxycholic acid 3-glucuronide	Others	Metabolic Disease Cancer
Glycochenodeoxycholic acid 3-glucuronide is a type of steroid glucuronide and a plasma metabolite that can be used for biomarker research in diabetes and hepatocellular carcinoma (HCC) .

HY-149063

Antitumor agent-92	Apoptosis	Cancer
Antitumor agent-92, an Icaritin (HY-N0678) derivative, causes arrest at the G0/G1 phase in the cell cycle and induces cell apoptosis. Antitumor agent-92 has the potential for hepatocellular carcinoma (HCC) research .

HY-141813

Autophagy-IN-C1

Autophagy Cancer

Autophagy-IN-C1 not only induces apoptosis but also blocks autophagy in hepatocellular carcinoma (HCC) cells.
HY-151461

CHNQD-01255

Others Cancer

CHNQD-01255 is an orally active Arf-GEFs inhibitor with potent anti-hepatocellular carcinoma (HCC) efficacy .

Autophagy-IN-C1	Autophagy	Cancer
Autophagy-IN-C1 not only induces apoptosis but also blocks autophagy in hepatocellular carcinoma (HCC) cells.

CHNQD-01255	Others	Cancer
CHNQD-01255 is an orally active Arf-GEFs inhibitor with potent anti-hepatocellular carcinoma (HCC) efficacy .

HY-19832

SC66 5 Publications Verification	Akt Apoptosis	Cancer
SC66 is an Akt inhibitor, reduces cell viability in a dose- and time-dependent manner, inhibits colony formation and induces apoptosis in hepatocellular carcinoma (HCC) cells.

HY-N2591

Isocorydine	Endogenous Metabolite	Cancer
Isocorydine is isolated from Dicranostigma leptopodum (Maxim.) Fedde (DLF). Isocorydine combines with Doxorubicin (DOX) has a promising potential to eradicate hepatocellular carcinoma (HCC) .

HY-W013514

2-Acetamidofluorene	Others	Cancer
2-Acetamidofluorene is a potent carcinogenan. 2-Acetamidofluorene is can be used fot induction of hepatocellular carcinoma (HCC) and multiple primary tumours .

HY-N2591A

Isocorydine hydrochloride	Endogenous Metabolite	Cancer
Isocorydine hydrochloride is isolated from Dicranostigma leptopodum (Maxim.) Fedde (DLF). Isocorydine hydrochloride combines with Doxorubicin (DOX) has a promising potential to eradicate hepatocellular carcinoma (HCC) .

HY-121160

Amiprilose SM1213; Therafectin	Bacterial	Infection Cancer
Amiprilose (SM1213; Therafectin) is a potent inhibitor against Hepatocellular carcinoma (HCC). Amiprilose induces lymphokine-induced macrophage activation directly to kill Listeria monocytogenes .

HY-N7507A

Sempervirine nitrate	Wnt β-catenin	Cancer
Sempervirine is an alkaloid derived from Gelsemium elegans Benth.. Sempervirine inhibits the proliferation of hepatocellular carcinoma (HCC) cells and induces apoptosis by regulating Wnt/β-catenin pathway .

HY-N4168B

Methyl chlorogenate	Others	Cancer
Methyl chlorogenate is an antioxidant, and has radical scavenging activity. Methyl chlorogenate is an anti-inflammatory agent. Methyl chlorogenate also inhibits hepatocellular carcinoma (HCC) cell proliferation and metastasis .

HY-147187

MNK8	STAT Apoptosis Bcl-2 Family Survivin	Cancer
MNK8 is a potent STAT3 (signal transducer and activator of transcription 3) inhibitor. MNK8 inhibits STAT3 activation and reduced its DNA binding ability. MNK8 shows good growth inhibition against hepatocellular carcinoma (HCC) cells. MNK8 induces apoptosis in HCC cells. MNK8 reduces prosurvival proteins expression and migration/invasion of HCC cells .

HY-150072

DS89002333	PKA	Cancer
DS89002333 is an orally active and potent PRKACA inhibitor, with an IC₅₀ of 0.3 nM. DS89002333 shows good anti-tumor activity in an FL-HCC patient-derived xenograft model (expressing the DNAJB1-PRKACA fusion gene). DS89002333 can be used in study of fibrolamellar hepatocellular carcinoma (FL-HCC) .

HY-P99353

Ascrinvacumab Anti-ACVRL1 / ALK-1 Reference Antibody (ascrinvacumab); PF-03446962	Anaplastic lymphoma kinase (ALK)	Cancer
Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a K_d value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC) .

HY-160765

WNTinib APS-8-100-2	Wnt Apoptosis	Cancer
WNTinib (APS-8-100-2) is a multi-kinase inhibitor that selectively antagonizes β-catenin (CTNNB1) mutated hepatocellular carcinoma (HCC). WNTinib downregulates oncogenicWntsignaling by inhibiting KIT/MAPK and downstream EZH2 activation .

HY-132177

α-L-Fucosidase, Microorganism 1 Publications Verification EC 3.2.1.51; FUC	Others	Cancer
α-L-Fucosidase, Microorganism (EC 3.2.1.51) is an enzyme that catalyzes the chemical reaction. Serum activity of α-L-Fucosidase, Microorganism, a lysosomal enzyme present in all mammalian cells, has been proposed as a marker of hepatocellular carcinoma (HCC) .

HY-N6623

Malvidin-3-galactoside chloride	Apoptosis Endogenous Metabolite Reactive Oxygen Species	Cancer
Malvidin-3-galactoside chloride, an anthocyanin monomer, induces hepatocellular carcinoma (HCC) cells cycle arrest and apoptosis. Malvidin-3-galactoside chloride inhibits the production and accumulation of ROS. Malvidin-3-galactoside chloride has anti-tumor function .

HY-100492

Fisogatinib 1 Publications Verification BLU-554	FGFR	Cancer
Fisogatinib (BLU-554) is a potent, highly selective and orally active fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC₅₀ of 5 nM. Fisogatinib has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signalling .

HY-155248

HL23	HDAC	Cancer
HL23 is a histone deacetylase (HDAC) inhibitor with activity against hepatocellular carcinoma (HCC). HL23 enhances acetylation of the TXNIP promoter and upregulates TXNIP expression, thereby mediating potassium channel activity and triggering TXNIP-dependent potassium deprivation. HL23 inhibits HCC progression and metastasis and has a synergistic effect with Sorafenib (HY-10201) and is more potent than Sorafenib+Vorinostat (HY-10221) .

HY-137506

XST-14 1 Publications Verification	ULK p38 MAPK TGF-β Receptor Anaplastic lymphoma kinase (ALK) CaMK Apoptosis	Cancer
XST-14 is a potent, competitive and highly selective ULK1 inhibitor with an IC₅₀ of 26.6 nM. XST-14 induces autophagy inhibition by reducing the phosphorylation of the ULK1 downstream substrate. XST-14 induces apoptosis in hepatocellular carcinoma (HCC) cells and has antitumor effects .

HY-149475

VEGFR-2-IN-33	VEGFR	Cancer
VEGFR-2-IN-33 (Compound 4d) is a VEGFR inhibitor (IC₅₀: 61.04 nM). VEGFR-2-IN-33 inhibits HepG2 cell proliferation with an IC₅₀ of 4.31 nM. VEGFR-2-IN-33 can be used for research of hepatocellular carcinoma (HCC) .

HY-15897

LDN-212854 1 Publications Verification	TGF-β Receptor	Cancer
LDN-212854 is a bone morphogenetic protein (BMP) inhibitor that potently inhibits ALK2 (IC₅₀: 1.3 nM). LDN-212854 also inhibits ALK1 (IC₅₀: 2.40 nM). LDN-212854 can be used in the research of fibrodysplasia ossificans progressive and cancers, such as hepatocellular carcinoma (HCC) .

HY-101519

BETd-260 1 Publications Verification ZBC 260	PROTACs Epigenetic Reader Domain Apoptosis	Cancer
BETd-260 (ZBC 260) is a PROTAC connected by ligands for Cereblon and BET, with as low as 30 pM against BRD4 protein in RS4;11 leukemia cell line . BETd-260 potently suppresses cell viability and robustly induces apoptosis in hepatocellular carcinoma (HCC) cells .

HY-150538

STAT3-IN-12	STAT Apoptosis	Cancer
STAT3-IN-12 is a potent STAT3 signal inhibitor that can inhibit IL-6 induced JAK/STAT3 signalling pathway activation. STAT3-IN-12 inhibits cancer cell growth, migration, and induce cell apoptosis as well as cycle arrest. STAT3-IN-12 can be used in cancer-related research, such as hepatocellular carcinoma (HCC) and oesophageal carcinoma .

HY-111226

GSK5182 2 Publications Verification	Estrogen Receptor/ERR Reactive Oxygen Species	Cardiovascular Disease Cancer
GSK5182 is a highly selective and orally active inverse agonist of estrogen-related receptor γ (ERRγ) with an IC₅₀ of 79 nM. GSK5182 does not interact with other nuclear receptors, including ERRα or ERα. GSK5182 also induces reactive oxyen species (ROS) generation in hepatocellular carcinoma (HCC) .

HY-115902

FGFR4-IN-7	FGFR Apoptosis	Cancer
FGFR4-IN-7 (Compound C3) is a covalent reversible FGFR4 inhibitor with an IC₅₀ value of 0.42 μM. FGFR4-IN-7 induces apoptosis via the FGFR4 signaling pathway blockage. FGFR4-IN-7 can be used for the research of hepatocellular carcinoma (HCC) .

HY-N7073

Silymarin 4 Publications Verification	SARS-CoV	Infection Neurological Disease Inflammation/Immunology Cancer
Silymarin is an extract of the milk thistle (Silybum marianum). Silymarin is an effective SARS-CoV-2 main protease (M ^pro) inhibitor. Silymarin can significantly reduce tumor cell proliferation, angiogenesis as well as insulin resistance. Silymarin has the chemopreventive effect on hepatocellular carcinoma (HCC). Silymarin has the potential for COVID-19 research .

HY-130173

Bafilomycin C1	Bacterial Fungal Na+/K+ ATPase Apoptosis Antibiotic	Infection Cancer
Bafilomycin C1 is a macrolide antibiotic isolated from Streptomyces sp. Bafilomycin C1 is a potent, specific and reversible inhibitor of vacuolar-type H ⁺-ATPases (V-ATPases). Bafilomycin C1 inhibits growth of gram-positive bacteria and fungi . Bafilomycin C1 induces cell apoptosis and can be used for the study of hepatocellular carcinoma (HCC) .

HY-162143

SKI-349	SphK Akt mTOR	Cancer
SKI-349 is a dual-targeted inhibitor of sphingosine kinase 1/2 (SPHK1/2) and microtubule assembly (MDA). SKI-349 has anticancer activity. SKI-349 can inhibit the vitality, invasion, and AKT/mTOR signaling pathway of liver cells .

HY-19345

Vacquinol-1 NSC13316
Vacquinol-1 (NSC13316) is a MKK4-specific activator that activates MAPK pathways . Vacquinol-1 specifically induces human glioblastoma cell (GC) death, attenuates tumor progression and prolongs survival in a glioblastoma multiforme (GBM) mouse model . Vacquinol-1 also induces apoptosis in hepatocellular carcinoma (HCC)cell .

HY-146395

HBV-IN-23	HBV DNA/RNA Synthesis Apoptosis	Infection Cancer
HBV-IN-23 (Compound 5k) is an inhibitor of HBV DNA replication with an IC₅₀ of 0.58 μM. HBV-IN-23 inhibits HBV DNA replication in both agent sensitive and resistant HBV strains. HBV-IN-23 shows anti-hepatocellular carcinoma cell (HCC) activities. HBV-IN-23 induces HepG2 cells apoptosis .

HY-19345A

Vacquinol-1 dihydrochloride NSC13316 dihydrochloride	Others	Cancer
Vacquinol-1 (NSC13316) dihydrochloride is a MKK4-specific activator that activates MAPK pathways . Vacquinol-1 dihydrochloride specifically induces human glioblastoma cell (GC) death, attenuates tumor progression and prolongs survival in a glioblastoma multiforme (GBM) mouse model . Vacquinol-1 dihydrochloride also induces apoptosis in hepatocellular carcinoma (HCC)cell .

HY-142684

Pyruvate Carboxylase-IN-1	Others	Cancer
Pyruvate Carboxylase-IN-1 (compound 37) is a potent inhibitor of pyruvate carboxylase (PC) with IC₅₀s of 0.204 and 0.104 μM in cell lysate-based and cell-based PC activity, respectively. Pyruvate Carboxylase-IN-1 is a natural analog of erianin. Pyruvate Carboxylase-IN-1 inhibites the enzymatic activity of PC, mediating the anticancer effect in human hepatocellular carcinoma (HCC) .

HY-142685

Pyruvate Carboxylase-IN-2	Others	Cancer
Pyruvate Carboxylase-IN-2 (compound 29) is a potent inhibitor of pyruvate carboxylase (PC) with IC₅₀s of 0.065 and 0.097 μM in cell lysate-based and cell-based PC activity, respectively. Pyruvate Carboxylase-IN-2 is a natural analog of erianin. Pyruvate Carboxylase-IN-2 inhibites the enzymatic activity of PC, mediating the anticancer effect in human hepatocellular carcinoma (HCC) .

HY-119833

Rubone	MicroRNA	Cancer
Rubone, a chalcone analog, is a modulator of miR-34a. Rubone upregulates miR-34a expression in a p53 dependent manner, downregulates the downstream target Bcl-2 and Cyclin D1 expression, and suppresses hepatocellular carcinoma (HCC) growth in vivo. Rubone enhances the anticancer effect of Paclitaxel (PTX; HY-B0015) in PTX-resistant prostate cancer cell lines by reversing the expression of miR-34a downstream targets .

HY-162259

QC-182	PROTACs Histone Acetyltransferase	Cancer
QC-182 is a potent PROTAC degrader of p300/CBP. QC-182 reduces p300 protein in the SK-HEP-1 cells (DC₅₀ = 93nM). QC-182 potently and effectively inhibits cell growth in the SK-HEP-1 and JHH7 cell lines with IC₅₀ values of 0.733 and 0.477 μM, respectively. QC-182 can be used for the research of hepatocellular carcinoma (HCC) .

HY-100008

Peretinoin 3 Publications Verification NIK333	RAR/RXR SphK Autophagy HCV	Infection Cancer
Peretinoin is an oral acyclic retinoid with a vitamin A-like structure that targets retinoid nuclear receptors such as retinoid X receptor (RXR) and retinoic acid receptor (RAR). Peretinoin reduces the mRNA level of sphingosine kinase 1 (SPHK1) in vitro by downregulating a transcription factor, Sp1 . Peretinoin prevents the progression of non-alcoholic steatohepatitis (NASH) and the development of hepatocellular carcinoma (HCC) through activating the autophagy pathway by increased Atg16L1 expression . Peretinoin inhibits HCV RNA amplification and virus release by altering lipid metabolism with a EC₅₀ of 9 μM .

HY-155046

FGFR4-IN-14	FGFR	Cancer
FGFR4-IN-14 (Compound 27i) is a FGFR4 inhibitor (IC₅₀: 2.4 nM. FGFR4-IN-14 inhibits the proliferation of V550L and N535K mutant strains, with IC₅₀s of 21 nM, 2.5 nM, 171 nM against huh7, BaF3/ETV6-FGFR4-V550L and BaF3/ETV6-FGFR4-N535K cells respectively. FGFR4-IN-14 has potent antitumor efficacy in the Huh7 xenograft model. FGFR4-IN-14 can be used for research of hepatocellular carcinoma (HCC) .

Anti-Liver Cancer Compound Library	1816 compounds
Liver cancer is one of the leading malignancies which occupies the second position in cancer deaths worldwide, becoming serious threat to human health. Hepatocellular carcinoma (HCC), also known as hepatoma is the most common type accounting for approximately 90% of all liver cancers. Current evidence indicates that during hepatocarcinogenesis, two main pathogenic mechanisms prevail: (1) cirrhosis associated with hepatic regeneration after tissue damage caused by hepatitis infection, toxins or metabolic influences, and (2) mutations occurring in single or multiple oncogenes or tumor suppressor genes. Both mechanisms have been linked with alterations in several important cellular signaling pathways. These include the RAF/MEK/ERK pathway, PI3K/AKT/mTOR pathway, WNT/b-catenin pathway, insulin-like growth factor pathway, c-MET/HGFR pathway , etc. MCE offers a unique collection of 1816 compounds with identified and potential anti-liver cancer activity. MCE anti-liver cancer compound library is a useful tool for anti-liver cancer drugs screening and other related research.

Ascrinvacumab Anti-ACVRL1 / ALK-1 Reference Antibody (ascrinvacumab); PF-03446962	Anaplastic lymphoma kinase (ALK)	Cancer
Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a K_d value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC) .

Codrituzumab GC33; RO5137382	Inhibitory Antibodies	Cancer
Codrituzumab is a monoclonal antibody targeting GPC3 (glypican-3). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth .

Isocorydine	Alkaloids Structural Classification Monophenols other families Classification of Application Fields Source classification Phenols Plants Isoquinoline Alkaloids Disease Research Fields Cancer	Endogenous Metabolite
Isocorydine is isolated from Dicranostigma leptopodum (Maxim.) Fedde (DLF). Isocorydine combines with Doxorubicin (DOX) has a promising potential to eradicate hepatocellular carcinoma (HCC) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks